ClinicalTrials.gg
CompletedNCT07125638Updated Aug 15, 2025

Long-term Follow-up After OAGB

An observational study in Obesity, Morbid, Obesity, Abdominal and Ona Anastomosis Gastric Bypass, sponsored by Azienda Sanitaria Locale Napoli 2 Nord. Completed at 1 site in Italy. Open to participants aged 18 Years to 67 Years. Per ClinicalTrials.gov, last updated 2025-08-15.

Sponsored by Azienda Sanitaria Locale Napoli 2 Nord · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
2,368
Ages
18 Years to 67 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 54 studies in Obesity, Morbid with a site in Italy — 11 open to participants now, 12 under way, none of them phase 3. Obesity, Morbid · Italy.

Enrollment
3rd of 29
2,368 · median 180
Started
2018
the only one that year
Observational
29 of 54
3 open now
Registered
53rd of 54
by date
Lead sponsor
3 of 54
Azienda Sanitaria Locale Napoli 2 Nord

Among the 54 studies in Obesity, Morbid with a site in Italy, this one is the 3rd largest by enrollment of the 29 observational ones that give a count, is the only one that started in 2018, is one of 29 observational ones, and was the 53rd registered.

Obesity, Morbid

941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.

Browse Obesity, Morbid studies →

Open to participants now

11 of the 54 studies in Obesity, Morbid with a site in Italy are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 67 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Obesity, Morbid with a site in Italy, or all of them as a file.
02

Study summary

This study follows patients who have undergone one-anastomosis gastric bypass (OAGB), a type of weight-loss surgery, to check for changes in the stomach and esophagus over time. All patients have an upper endoscopy before surgery and then again 1, 3, and 5 years later, even if they have no symptoms. The main goal is to see how often problems like bile reflux or ulcers at the surgical join (marginal ulcers) occur. The study also looks at whether patients' symptoms match what is seen during endoscopy.

Read the detailed description

This study is designed to learn more about changes in the digestive system after one-anastomosis gastric bypass (OAGB), a widely used weight-loss operation. While this surgery is effective for reducing excess weight and improving obesity-related health problems, some people may develop changes in the stomach or esophagus over time, such as bile reflux (backflow of bile into the stomach or esophagus) or marginal ulcers (sores at the site where the stomach is joined to the small intestine).

To better understand how often these problems occur, and whether they cause symptoms, the study follows patients for at least 5 years after surgery. All participants have an upper endoscopy (a camera test that looks at the esophagus, stomach, and the join with the small intestine) before surgery, and then again 1, 3, and 5 years afterwards. These check-ups are done even if the patient feels well, to detect any hidden changes early.

The study also compares what patients report in symptom questionnaires-covering issues like heartburn, regurgitation, or stomach discomfort-with what is actually seen during endoscopy. This will help doctors understand how well symptoms match the real condition of the digestive tract.

By using the same protocol across several specialized bariatric centers, and including all eligible patients, the study aims to provide reliable, long-term data to guide follow-up care after OAGB. The findings could help refine patient monitoring, improve early detection of problems, and identify risk factors that can be addressed to prevent complications.

03

Conditions studied

  • Obesity, Morbid
  • Obesity, Abdominal
  • Ona Anastomosis Gastric Bypass
  • GERD
  • Bile Reflux Gastritis
04

Who can participate

Ages eligible
18 Years to 67 Years
Sexes eligible
All
Sampling method
Probability sample

Study population

  • Major postoperative complication within 30 days after OAGB (Clavien-Dindo grade III or IV).
  • Any subsequent abdominal surgery after OAGB (e.g., cholecystectomy, incisional hernia repair) prior to planned endoscopic follow-up.
  • Prior or concomitant revisional bariatric procedure that could impair esophageal motility.
  • Total clinical follow-up shorter than 12 months.
  • Chronic corticosteroid use.
  • Chronic nonsteroidal anti-inflammatory drug (NSAID) use.
  • Preoperative upper endoscopy showing Los Angeles grade ≥ B esophagitis.
  • Preoperative hiatal hernia > 5 cm.
  • Severe, proton-pump-inhibitor-resistant GERD symptoms or advanced lower esophageal sphincter (LES) incompetence preoperatively.
  • Inability or unwillingness to provide informed consent or comply with follow-up.

Eligibility criteria

Inclusion Criteria:

    • Age ≥ 18 years.

      • Meets IFSO indications for bariatric surgery ( > 40 kg/m², or BMI > 35 kg/m² with obesity-related comorbidities).
      • Candidate for primary one-anastomosis gastric bypass (OAGB).
      • Preoperative upper endoscopy completed as part of standardized work-up.
      • Helicobacter pylori screened preoperatively and (if positive) eradication therapy completed before surgery.
      • Able and willing to attend scheduled postoperative upper endoscopies (at approximately 1, 3, and 5 years) regardless of symptoms.
      • Able to complete patient-reported outcome instruments (GERD-HRQL and abbreviated GSRS).
      • Provided written .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
2,368 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Incidence of Bile Reflux and Marginal Ulcers Assessed by Standardized Endoscopic Follow-up After OAGB

    The primary outcome is the proportion of patients presenting with bile reflux following one-anastomosis gastric bypass (OAGB). Findings are determined through standardized upper gastrointestinal endoscopy performed at 1, 3, and 5 years postoperatively. Bile reflux is defined as the presence of visible bile in the gastric pouch or esophagus during endoscopy, with or without associated mucosal changes. .

    Time frame: 1 years follow-up

  2. Incidence of Bile Reflux and Marginal Ulcers Assessed by Standardized Endoscopic Follow-up After OAGB

    The primary outcome is the proportion of patients presenting with bile reflux following one-anastomosis gastric bypass (OAGB). Findings are determined through standardized upper gastrointestinal endoscopy performed at 1, 3, and 5 years postoperatively. Bile reflux is defined as the presence of visible bile in the gastric pouch or esophagus during endoscopy, with or without associated mucosal changes. .

    Time frame: 3 years follow-up

  3. Incidence of Bile Reflux and Marginal Ulcers Assessed by Standardized Endoscopic Follow-up After OAGB

    The primary outcome is the proportion of patients presenting with bile reflux following one-anastomosis gastric bypass (OAGB). Findings are determined through standardized upper gastrointestinal endoscopy performed at 1, 3, and 5 years postoperatively. Bile reflux is defined as the presence of visible bile in the gastric pouch or esophagus during endoscopy, with or without associated mucosal changes. .

    Time frame: 5 years follow-up

  4. Incidence of Marginal Ulcers After One-Anastomosis Gastric Bypass

    The primary outcome is the proportion of patients developing marginal ulcers following one-anastomosis gastric bypass (OAGB). Marginal ulcers are defined as mucosal ulcerations located at the gastrojejunal anastomosis, confirmed by direct visualization during standardized upper gastrointestinal endoscopy. Endoscopy is performed at 1, 3, and 5 years postoperatively, regardless of the presence or absence of symptoms. Lesions are classified according to established endoscopic morphological criteria, and their size, depth, and location are systematically recorded.

    Time frame: 1 years follow-up

  5. Incidence of Marginal Ulcers After One-Anastomosis Gastric Bypass

    The primary outcome is the proportion of patients developing marginal ulcers following one-anastomosis gastric bypass (OAGB). Marginal ulcers are defined as mucosal ulcerations located at the gastrojejunal anastomosis, confirmed by direct visualization during standardized upper gastrointestinal endoscopy. Endoscopy is performed at 1, 3, and 5 years postoperatively, regardless of the presence or absence of symptoms. Lesions are classified according to established endoscopic morphological criteria, and their size, depth, and location are systematically recorded.

    Time frame: 3 years follow-up

  6. Incidence of Marginal Ulcers After One-Anastomosis Gastric Bypass

    The primary outcome is the proportion of patients developing marginal ulcers following one-anastomosis gastric bypass (OAGB). Marginal ulcers are defined as mucosal ulcerations located at the gastrojejunal anastomosis, confirmed by direct visualization during standardized upper gastrointestinal endoscopy. Endoscopy is performed at 1, 3, and 5 years postoperatively, regardless of the presence or absence of symptoms. Lesions are classified according to established endoscopic morphological criteria, and their size, depth, and location are systematically recorded.

    Time frame: 5 years follow-up

Secondary outcomes

  1. Correlation Between Gastroesophageal Symptoms and Endoscopic Findings After OAGB

    The secondary outcome is the level of agreement between patient-reported gastroesophageal symptoms, assessed using the GERD-Health Related Quality of Life (GERD-HRQL) questionnaire, and objective findings on standardized upper gastrointestinal endoscopy at 1, 3, and 5 years after one-anastomosis gastric bypass (OAGB). Concordance is measured using the Cohen's kappa statistic, with symptoms recorded as present/absent and endoscopic lesions classified according to the Los Angeles grading system for esophagitis and established criteria for gastritis and ulcer disease.

    Time frame: 1 year follow-up

  2. Correlation Between Gastroesophageal Symptoms and Endoscopic Findings After OAGB

    The secondary outcome is the level of agreement between patient-reported gastroesophageal symptoms, assessed using the GERD-Health Related Quality of Life (GERD-HRQL) questionnaire, and objective findings on standardized upper gastrointestinal endoscopy at 1, 3, and 5 years after one-anastomosis gastric bypass (OAGB). Concordance is measured using the Cohen's kappa statistic, with symptoms recorded as present/absent and endoscopic lesions classified according to the Los Angeles grading system for esophagitis and established criteria for gastritis and ulcer disease.

    Time frame: 3 year follow-up

  3. Correlation Between Gastroesophageal Symptoms and Endoscopic Findings After OAGB

    The secondary outcome is the level of agreement between patient-reported gastroesophageal symptoms, assessed using the GERD-Health Related Quality of Life (GERD-HRQL) questionnaire, and objective findings on standardized upper gastrointestinal endoscopy at 1, 3, and 5 years after one-anastomosis gastric bypass (OAGB). Concordance is measured using the Cohen's kappa statistic, with symptoms recorded as present/absent and endoscopic lesions classified according to the Los Angeles grading system for esophagitis and established criteria for gastritis and ulcer disease.

    Time frame: 5 year follow-up

07

Study locations

1 site
  • Azienda Sanitaria Locale Napoli 2 Nord - U.O.C. Chirurgia Generale, P.O. "Anna Rizzoli", Lacco Ameno, Naples, Italy
    Naples, naples 80131, Italy
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2018 to primary completion in Jan 2023, 60 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2025
First posted
Aug 15, 2025
StartActual
Jan 1, 2018
Primary completionActual
Jan 1, 2023
CompletionActual
Mar 1, 2023
Last update
Aug 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07125638
Lead sponsor
Azienda Sanitaria Locale Napoli 2 Nord
Responsible party
Francesco Pizza (MD,PhD, Responsible for the Bariatric and Metabolic Surgery unit, Azienda Sanitaria Locale Napoli 2 Nord) — Principal investigator
First posted
Aug 15, 2025
Start date
Jan 1, 2018
Primary completion
Jan 1, 2023
Completion
Mar 1, 2023
Last update
Aug 15, 2025

Study contacts

francesco pizza, PhD
principal investigator · Azienda Sanitaria Locale Napoli 2 Nord

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion